Skip to content
Screener

Tandem Diabetes Care TNDM International — Sales

Similar metrics at other companies

Linde logo
LINOther International — Sales
$2.81B+3.8%
AdvanSix logo
ASIXInternational — Sales
$66.96M+30.4%
Sysco logo
SYYInternational Foodservice Operations — Sales
$3.89B+12.4%
GTL
GTLSChina — Sales
$125.35M-11.3%
Astronics logo
ATROAsia — Sales
$18.32M+65.8%
Astronics logo
ATROEurope — Sales
$38.35M+10.1%

Other financials

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Operating income-$13.8M+73.4%
Net income-$21.2M+59.6%
EPS (diluted)-$0.31+60.3%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
Operating cash flow-$34.6M-265%
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation

See full
Market cap$1.56B+128%
Enterprise value$2.23B+109%
P/S1.5×+0.8×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001438133-26-000125
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
United States$179,292$170,209$340,135$320,841
International75,26870,469161,646154,259
Total Sales$254,560$240,678$501,781$475,100

Item 1. Financial Statements.

FAQ

What is Tandem Diabetes Care's international — sales?
Tandem Diabetes Care (TNDM) reported international — sales of $75.27M in Q2 2026.
How has Tandem Diabetes Care's international — sales changed year-over-year?
Tandem Diabetes Care's international — sales increased by 6.8% year-over-year, from $70.47M to $75.27M.
What is the long-term trend for Tandem Diabetes Care's international — sales?
Over 4 years (2021 to 2025), Tandem Diabetes Care's international — sales has grown at a 14.7% compound annual growth rate (CAGR), from $177.89M to $307.8M.
What does international — sales mean?
This metric represents the total revenue generated from product sales and services within geographic regions outside of the company's primary domestic market. It serves as a key indicator of the firm's global market penetration and the scalability of its product portfolio in international healthcare systems. Growth in this metric reflects successful expansion efforts and the adoption rate of medical devices in non-domestic territories.

Ask your AI about Tandem Diabetes Care's international — sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude